Kadmon to Present at the 15th Annual BIO Investor Forum
October 17 2016 - 9:00AM
Business Wire
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W.
Waksal, M.D., President and Chief Executive Officer, will present
an overview of the Company and its clinical programs at the 15th
Annual BIO Investor Forum on Tuesday, October 18 at 10:00 a.m. PT
in San Francisco, California.
A live audio webcast of the presentation may be accessed on the
Investors section of the Kadmon website at www.kadmon.com. A replay
of the webcast will be available for 90 days.
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical
company focused on developing innovative products for significant
unmet medical needs. We have a diversified product pipeline in
autoimmune and fibrotic diseases, oncology and genetic
diseases.
Safe Harbor Statement
This press release contains forward-looking statements. Such
statements may be preceded by the words “may,” “will,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “targets,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or “continue” or the negative of these terms or other
similar expressions. Forward-looking statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. More detailed information about Kadmon and the risk
factors that may affect the realization of forward-looking
statements is set forth in the Company's filings with the U.S.
Securities and Exchange Commission (SEC), including the Company's
prospectus filed pursuant to Rule 424(b) under the Securities Act
of 1933, as amended, with the SEC on July 27, 2016. Investors and
security holders are urged to read these documents free of charge
on the SEC's web site at www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161017005168/en/
For Kadmon Holdings, Inc.Ellen Tremaine, 646-490-2989Investor
Relationsellen.tremaine@kadmon.comorMaeve Conneighton,
212-600-1902maeve@argotpartners.com
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Apr 2023 to Apr 2024